AstraZeneca, Daiichi Sankyo announce Enhertu plus pertuzumab demonstrated clinically meaningful improvement as 1st-line therapy for patients with metastatic breast cancer

DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care

Shin-Etsu Chemical and Hokkaido University develop lipid nanoparticle production system capable of both small-batch, high-mix production

Injection filter needle market to reach $1.73 billion in 2025

Rising demands and advancements in eye care drive growth

Novartis to invest $23 billion on expansion of manufacturing and R&D facilities in US

Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities

Biocon Biologics announces USFDA approval for Jobevne biosimilar Bevacizumab

Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis

Granules India completes acquisition of Senn Chemicals

Strengthening capabilities in Peptide Therapeutics and CDMO services

Shilpa’s Unit-2 passes second consecutive FDA inspection with no 483s

Raichur site is the group’s largest API facility and part of a wider network of seven sites

Anurag Mantri appointed as President of Glenmark Pharmaceuticals

Mantri will replace V. S. Mani, Executive Director & Global Chief Financial Officer of the company as he has conveyed his decision to opt for early retirement

Hyderabad based CSIR institutes playing pivotal role in drug discovery and genetic diagnostics: Dr. Jitendra Singh

In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025

Metropolis to acquire Dehradun’s Ahujas’ Pathology & Imaging Centre for Rs. 35.01 Cr